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Abstract: Antibiotic-resistant infections present a serious health concern worldwide. It is estimated
that there are 2.8 million antibiotic-resistant infections and 35,000 deaths in the United States every
year. Such microorganisms include Acinetobacter, Enterobacterioceae, Pseudomonas, Staphylococcus
and Mycobacterium. Alternative treatment methods are, thus, necessary to treat such infections.
Bacteriophages are viruses of bacteria. In a lytic infection, the newly formed phage particles lyse
the bacterium and continue to infect other bacteria. In the early 20th century, d’Herelle, Bruynoghe
and Maisin used bacterium-specific phages to treat bacterial infections. Bacteriophages are being
identified, purified and developed as pharmaceutically acceptable macromolecular “drugs,” undergoing strict quality control. Phages can be applied topically or delivered by inhalation, orally or
parenterally. Some of the major drug-resistant infections that are potential targets of pharmaceutically
prepared phages are Pseudomonas aeruginosa, Mycobacterium tuberculosis and Acinetobacter baumannii.
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1. Introduction: Bacteriophage Treatment of a Serious Infection

https://doi.org/10.3390/ph14010034

A 68-year-old man with diabetes developed necrotizing pancreatitis that was complicated by a pancreatic pseudocyst infected with a multi-drug-resistant strain of Acinetobacter
baumannii [1]. A. baumannii is a Gram-negative nosocomial pathogen involved in bacteremia, meningitis and pulmonary infections with a high mortality rate. It is one of the
“ESKAPE” microorganisms that are grouped together because of the common occurrence
of multi-drug-resistance in the group. These microorganisms include Enterococcus faecium,
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa
and Enterobacter species. The condition of the patient was deteriorating rapidly despite
antibiotic treatment, to which he was obviously not responding. Bacteriophage therapy
was initiated as part of an emergency investigational new drug protocol.
Bacteriophages are viruses of bacteria. Phages can cause either lytic or lysogenic
infections in bacteria after attaching to a receptor or receptors on the bacterial surface and
delivering their genome into the bacteria. In a lytic infection, the phage replicates and the
new phage particles lyse the bacterium and continue to infect other bacteria (Figure 1). In a
lysogenic infection, a DNA phage inserts its genetic material into the bacterial chromosome,
and the genome is passed on to daughter cells as the bacterium divides. The integrated
DNA may be activated by changes in environmental conditions to excise itself from the
chromosome, producing phage particles that become lytic [2–4].
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Figure 1. The lytic infection cycle of a bacteriophage. A phage particle attaches to a receptor on the surface of a host
bacterium and delivers its genome into the cytoplasm. Phage proteins and replicate genomes are synthesized and selfassemble into new phage particles that eventually lyse the bacterium. The phages then infect other bacteria with the
particular receptor (reproduced with permission from Kortright et al., 2019 [4]).

A large number of phage types that could specifically lyse A. baumannii were tested
against three strains of the bacterium obtained previously from the patient. The phages
had been collected by the Biological Defense Research Directorate of the Naval Medical
Research Center. Most of the phages, however, were not lytic towards the first clinical
bacterial sample obtained from the patient. Six phage types inhibited bacterial growth
for 20 h. Four of these phages were pooled and, when tested against the bacterial isolate
from the patient, had superior activity compared to each of the phages by themselves.
The patient showed clear clinical improvement within 2 days of the administration of
the phage cocktail containing a total of 5 × 109 particles. Initially, the phage mixture
was delivered through the percutaneous catheters draining the pseudocyst cavity, the
gallbladder and the intra-abdominal cavity and repeated every 6 to 12 h. Thirty-six hours
after the initiation of treatment, the phage cocktail was given intravenously [1]. This
treatment reversed the patient’s clinical decline, cleared the A. baumannii infection and
returned the patient to health.
The British bacteriologist Ernest Hankin (1896) noted the anti-Vibrio cholerae activity
of water from two rivers in India and suggested that a substance that could pass through
porcelain filters caused this observation and possibly limited cholera epidemics.
The Russian bacteriologist Gamaleya reported a similar phenomenon with Bacillus
subtilis [5]. The English bacteriologist Frederick Twort hypothesized in 1915 that the antibacterial effect could be mediated by a virus [6]. The French-Canadian microbiologist Felix
d’Herelle, at the Pasteur Institute in Paris, identified non-bacterial microorganisms from
the stools of patients suffering from severe hemorrhagic dysentery. These microorganisms
formed plaques in cultures of Shigella isolated from the patients [7]. In 1919, d’Herelle
used a phage preparation to treat a boy with dysentery who recovered within a day and
then three additional patients who started to recover within a day [8,9]. The first report of
phage therapy was published in 1921 by Richard Bruynoghe and Joseph Maisin [10]. They
injected bacteriophages into and around surgically opened staphylococcal skin lesions,
which regressed within 1–2 days.
2. Phages as Pharmaceuticals
2.1. Phage Isolation and Enrichment
The key processes in phage therapy protocols are phage selection and isolation.
The wrong choices can have fatal consequences [11]. Generally, two methods are used when
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choosing the appropriate phage for therapy: (1) A phage cocktail, such as Pyophage and
Intestiphage. These preparations have a broader spectrum of activity than a single phage
component and do not allow resistance to develop within a short time. (2) A pathogenspecific phage. Bacteria are isolated from the infection and tested for susceptibility to
particular phages isolated previously [11].
Samples for phage isolation are taken from environments where the bacterial host
can often be found, including soil, plant residues, fecal matter, wastewater and sewage
(Figure 2). Phages against Shigella dysenteriae 2308 were isolated from the New York City
sewage by Dubos et al. [12]. B_VpS_BA3 and vB_VpS_CA8 phages against Vibrio parahaemolyticus were isolated from sewage collected in China [13]. The vB_KpnP_IME337
phage against carbapenem-resistant Klebsiella pneumoniae was isolated from hospital sewage
in China [14]. Li et al. [15] isolated 54 novel phages against the same organism from medical
and domestic sewage wastewater. The newly isolated phage P545 had a relatively wide
host range and strong antibacterial activity.
Although there are differences in phage isolation, the basic principle of the methods is
the same as that developed by d’Herelle, and they are generally characterized as enrichment
procedures [16]. First, the presence of phages is detected in the collected sample. Selection
of the bacterial host is vital for the isolation of a phage in a recently acquired sample from
the environment. Solid samples are mixed with sterile broth or buffer and then subjected
to centrifugation and filtration [17]. Bacteria of interest are incubated overnight with the
environmental sample. The bacteria that have survived the attack of the lytic phages
are removed from the mixture by centrifugation or filtration, or both. The presence of
phages in the filtrate is then assessed by plaque assay or by qPCR. The isolated phages
have to be analyzed for their virulence, i.e., their ability to lyse target bacteria and the
range of bacterial types they are able to infect. In an alternate method, samples from
the environment are plated directly onto a lawn of particular bacteria and the presence
of plaques resulting from bacterial lysis is detected. The latter method has been used to
discover phages that lyse Escherichia coli and various bacteria from dental plaque and the
oral cavity [17,18].
In the procedure described in detail by Luong et al. [19], the target bacterial strain is
isolated and incubated with the phages. Then, after several agar plaque isolations, a single
plaque is cultivated overnight. The isolated phage genome is sequenced to screen and
identify lysogenic and deleterious genes. Phages are grown at liter scale, and the lysate is
purified to eliminate any bacteria and cellular debris by pressure-driven filtration through
filters of 0.8-, 0.45- and 0.22-µm pore size, followed by cross-flow ultra-filtration to eliminate
debris smaller than 100 kD. This process eliminates endotoxin, exotoxins, peptidoglycan,
nucleic acids and flagella. The phage particles are purified by CsCl density gradient
centrifugation and dialysis to eliminate the CsCl. Any residual endotoxin molecules are
removed by lipopolysaccharide-affinity chromatography. The last step ensures that the
phage preparations do not cause inflammation or endotoxic shock when administered to
patients [19].
Phages are expected to be found where the host bacteria reside. For example, phages
that infect intestinal bacteria can be isolated from fecal material, and phages against epidermal bacteria such as Staphylococcus aureus are most likely isolated from skin samples
or wound exudates. Identifying a phage against a particular bacterium is not straightforward, however. Whereas phages that lyse antibiotic-resistant Klebsiella pneumoniae
and Pseudomonas aeruginosa were readily isolated from sewage samples, phages against
antibiotic-resistant Acinetobacter baumannii were not found as frequently [20]. Furthermore,
phages against methicillin-resistant Staphylococcus aureus were identified only rarely.
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Figure 2. Stages of phage preparation. The environment (e.g., wastewater, farms and soil) is a source for all types of phages.
The presence of phages in the tested sample is determined by different methods such as the double layer agar method, spot
assays, the colorimetric method, the enrichment method or electron microscopy. The plaques that indicate lytic activity
are picked up and transferred for the determination of phage type, specificity, etc. A phage lysate is prepared. At this
stage, multiple procedures are performed to check for sterility (microbial contamination), toxicity (bacterial endotoxin or
lipopolysaccharide (LPS) quantification), bacterial DNA contamination and phage titer. The purified phage preparation
is stored.
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The choice of a host for phage isolation may also depend on the ease of culturing
the bacteria, as in the use of Mycobacterium smegmatis to isolate phages that will infect
other Mycobacterium species. M. smegmatis grows much faster than M. tuberculosis and thus
can produce a lawn on the appropriate agar surface for testing phage activity [17,20,21].
The isolated phages would then be tested further on the specific target Mycobacterium
species.
Swanstrom et al. [22] investigated the variables contributing to the generation of
high-titer phage stocks, using the agar layer method and coli phage T4r. The numbers of
virus particles and bacteria per plate, the incubation period, the amount of soft agar in the
agar layer as well as the broth volume used for virus extraction from the agar were found
to be significant factors. When these factors were optimized, stock concentrations in the
range of 1011 –1012 infectious particles/mL could be obtained [22].
Echeverría-Vega et al. [23] used a straightforward protocol for the isolation of bacteriophages from coastal organisms. They also validated the protocol for the isolation
of lytic bacteriophages for the fish pathogen bacterium Vibrio ordalii. This method has
particular utility for the recovery of bacteriophages for use as natural antimicrobial agents
in aquacultures. In the enrichment method, samples are added to the host produced in a
suitable medium, incubated and then centrifuged. The suspension containing the phage is
filtered and applied at different concentrations onto an agar medium with target bacteria.
The formed plaques are then counted. Thanks to the enrichment method, phages at low
concentration can reach the desired level in culture. Enrichment is an advantageous method
in cases where the amount of phages is low [24]. Numerous lytic phages were isolated
against Caulobacter and Asticcacaulis bacteria using the enrichment method [25]. Methods
such as spot testing, plaque testing, culture lysis and the calorimetric method are used in
the detection of newly isolated bacteriophages (Figure 2) [26–31]. In the spot assay [26],
bacteria are grown in Luria-Bertani broth, and after they are in the early log phase, they are
mixed with soft agar and poured onto a Petri plate with previously poured agar. A phage
filtrate is then placed on the soft agar and the plates are incubated overnight at 37 ◦ C, after
which bacterial lysis zones are counted [28]. In the double layer agar method, a bacterial
culture in the log phase is mixed with a purified phage preparation and incubated briefly
to allow for phage adsorption. This mixture is combined with soft agar and poured onto a
previously solidified agar layer to form a homogeneous layer. After incubation at 37 ◦ C for
24 h, plaque formation is observed, indicating phage activity. The plaques are resuspended
in Mg (SM) buffer [28].
2.2. Phage Production
Bacteriophages need a host cell to reproduce. Understanding the interactions between
host bacteria and bacteriophages is a crucial step in estimating the risks in production,
including possible mutations in either microorganism [32]. The production process may
also be affected by the nutrient composition, oxygenation, temperature and pH [33].
The substrate and temperature chosen for phage infection and bacterial growth are
important factors. Fermentation is an important stage for host bacteria to multiply and
produce bacteriophages. The sterilization step is performed to destroy undesired microorganisms. The bioreactor can be sterilized with heat, medium or a combination of these.
During the fermentation process, the injected air is filtered through an in-line membrane.
The air released after fermentation is filtered after it condenses [34].
Phages are grown basically in shaker flasks or stirred tank bioreactors. The latter are
used to carry out industrial-scale production of bacteriophages, which has been divided
into three different systems: batch, semi-continuous and continuous [35]. Each system
has brought about its distinct benefits and drawbacks, discussed earlier by Merabishvili
et al. [36]. Mancuso et al. [37] developed a production process that makes it possible to
obtain high titers of E. coli T3 phages at high concentrations (1011 PFU mL−1 ) using two
continuous stirred tank bioreactors. The first bioreactor is just for propagation of the host
bacteria at a steady-state growth rate by using controllable dilution rates and growth-
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limiting substrate (glucose). The second bioreactor is used for bacteriophage production
and is fed from the host bacteria of the first bioreactor. Besides achieving high phage
productivity of bacteriophages via the production process, the mutation risk of the host
bacteria potentially caused by bacteriophages is suppressed.
2.3. Phage Purification and Quality Control
For the pharmaceutical application of phages, it is necessary to first carry out the
purification process. The bacteriophage of interest is separated from host bacteria cells and
debris by centrifugation, microfiltration or by using these methods together. The potential
presence of any toxins in the preparations would be detrimental to the final pharmaceutical
product. A Chamberland filter of 0.1–1 µm was used for bacteriophage preparations to be
used in human trials [38]. It was recently clarified with a 0.2-µm filter pore size. Purification
procedures of phages should follow the Critical Quality Attributes (CQA) specification [34].
The process of removing endotoxins from phages is complex because lipopolysaccharide
forms micelles that have approximately the same size as phages. Therefore, extra purification methods such as ion exchange, affinity chromatography and solvent extraction are
needed for lysates of phage-infected Gram-negative bacteria [33].
Endotoxin. In bacteriophage products, endotoxin measurement is critical. Gel clot,
turbidimetric and chromatic methods are used for endotoxin determination in bacteriophage products. The Limulus amoebocyte lysate (LAL) assay is the most commonly used
method [39].
Transmission electron microscopy (TEM). The specific morphology of phages in a final
product can be viewed by transmission electron microscopy. Merabishvili et al. [40] used
TEM for confirmation of the presence of the expected virion morphologic particles as well
as their specific interaction with the target bacteria.
Titer. The process of determining phage concentration by dilution and plating with
susceptible cells is called titering or the plaque assay. A bacteriophage capable of productively infecting a cell is named a plaque-forming unit (PFU/mL) [41].
pH. In a therapeutic formulation, the pH value is very important. According to the
European Pharmacopoeia, the pH should be in the range 6.0–8.0 [42].
Nucleic Acid Contaminants. Because phages break down bacterial DNA, the presence
and concentration of nucleic acid residues in final products should be determined. qPCR
can be used for this purpose [33].
2.4. Phage Stability and Storage Conditions
Once solutions of phages are prepared, the biological properties of the phages have
to be preserved during storage. Freeze-drying, spray-drying or encapsulation methods
can be used to increase phage stability, as well as adding stabilizing additives to their
solutions [43–46]. The quality, safety and storage conditions of phages to be prepared for
use in treatment should be validated [47]. González-Menéndez et al. [48] investigated
different preservation techniques for the storage of Staphylococcus phages (phiIPLA88,
phiIPLA35, phiIPLA-RODI and phiIPLA-C1C). They evaluated the stability of phages at
different temperatures (−20, −80 and −196 ◦ C) and time periods (1, 6, 12 and 24 months).
They also investigated various stabilization enhancing agents, including disaccharides,
glycerol, sorbitol and skim milk. They showed that at −80 and −196 ◦ C, all phages showed
good viability after 24 months, regardless of the stabilizer [48].
2.5. Therapeutic Phages
Hyman et al. [17] proposed the following characteristics of phages to be used for
therapeutic purposes: (a) The phage should be virulent and be able to cause complete cytotoxicity to the target bacterium. (b) It should be exclusively lytic and should not become
temperate (i.e., lysogenic). (c) The phage should have the potential to transduce the host
bacteria. (d) It should have the desired host range. (e) It should be screened for toxin genes
that can affect the patient. Myoviridae, Siphoviridae and Podoviridae families are used com-
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monly for phage therapy [49,50]. There are approximately 800 phages against pathogens
such as Escherichia, Morganella, Klebsiella, Enterococcus, Pseudomonas, Staphylococcus and
Salmonella [31].
2.6. Magistral Phage
A “magistral preparation” or a “compounded prescription drug product”, in Europe
and the U.S., respectively, is defined as “any medicinal product prepared in a pharmacy in
accordance with a medical prescription for an individual patient” [33,34,48,51,52]. Such
preparations for a particular patient are mixed by a pharmacist from their individual
ingredients based on a prescription from a physician. The magistral formula is a practical
way for a medical doctor to personalize patient treatments to specific needs and to make
medications available that do not exist commercially. Some medicines, including natural
hormone combinations, are made as magistral preparations. It is expected that magistral
preparations will become more readily available as novel medicines are developed to treat
rare conditions.
A magistral phage preparation is prepared from a phage bank, which is a repository
of well-characterized microorganisms. A phage as an active pharmaceutical ingredient
(API) is produced using a suitable bacterial host. An approved laboratory then carries out
External Quality Assessments to test the API’s properties and quality. Active phage APIs
are evaluated for activity against the target. Finally, phage APIs are mixed with a suitable
carrier system. There are currently no guidelines on the preparation, formulation and use
of magistral phages [52].
2.7. Topical Administration of Phages
Several studies have shown that local and topical phage applications are successful. In
the treatment of infections caused by Staphylococci, Klebsiella, Pseudomonas, Proteus and Escherichia such as conjunctivitis, otitis, gingivitis, furunculosis, decubitis ulcer, open wound
infection, burns, osthitis (caused by fractures) and chronic suppurative fistulae, phage
cocktails have been applied locally [53–56]. A commercial product called PhagoBioDerm,
which targets P. aeruginosa, S. aureus and Streptococcus spp. and contains phages as well as
cipro-floxacin, can be applied directly over infected wounds. Goode et al. [57] eliminated
Salmonella contamination on chicken skin by using a lytic bacteriophage. Vieira et al. [58]
performed phage therapy against multidrug-resistant P. aeruginosa that had caused skin
infections. Thanks to phage therapy, the amount of P. aeruginosa 709 present in human skin
decreased by four orders of magnitude.
2.8. Pulmonary Phage Delivery
The first studies of inhaled phage therapy were carried out in the early 1960s. Such
treatments at a more advanced level were performed in Russia, Poland and Georgia. Although there have been many successful trials, some treatments have not had a positive
outcome because of a lack of phage variety, quality control and technical knowledge [59].
Phages may be encapsulated in polymers, nanoparticles and liposomes for stability during
storage, including storage as a freeze-dried preparation [60]. Liposome encapsulation
was found to facilitate phage entry into macrophages. Treatment of experimental K. pneumoniae-induced lobar pneumonia was more effective with liposome-entrapped phages
administered intraperitoneally as late as 3 days post-infection, whereas free phages provided a therapeutic effect only if they were administered at 1 day after infection [61].
Systemic side effects were reduced by the use of liposomal phage.
Liquid formulations using intranasal instillation and nebulization in phage studies
against respiratory infections on animal models are quite popular. Liquid phage formulations are stable, easily aerosolizable and easy to formulate compared to other carrier
systems [59]. Carrigy et al. [62] tested pre-exposure prophylactic aerosol delivery of the
anti-tuberculosis bacteriophage D29 as an option for protection against Mycobacterium tuberculosis infection and proposed that mycobacteriophage aerosols at sufficient doses may be
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protective against M. tuberculosis infection. The same group studied the titer reduction and
phage delivery rate of three inhalation devices (Vibrating Mesh Nebulizer, Jet Nebulizer
and Soft Mist Inhaler) with the mycobacteriophage D29 and showed that this method
of administration is suitable for phage delivery to lung tissue [63]. Golshahi et al. [64]
determined that the inhaled formulation of bacteriophages gives successful results in the
treatment of cystic fibrosis pulmonary infections.
2.9. Parenteral Phage Application
Phages are rapidly eliminated by the immune system when administered intravenously. Lin et al. [65] investigated the intravenous administration of the anti-pseudomonal
phage øPEV20 in P. aeruginosa-infected rats and demonstrated dose-dependent pharmacodynamics. Intravenous administration of øPEV20 at a dose of >104 PFU/mouse resulted in
rapid bacterial killing and >8-log10 CFU/mL reduction in bacterial load compared with
the initial inoculum and untreated controls at 2.5 h. However, treatment at a dose of
<104 øPEV20 PFU/mouse was ineffective against pan-drug-resistant P. aeruginosa. McVay
et al. [66] injected a P. aeruginosa phage cocktail with three different administration methods
(subcutaneous (s.c.), intramuscular (i.m.) and intraperitoneal (i.p.)) to P. aeruginosa-infected
mice. Without treatment, the survival rate was 6%, and i.p. administration of phage
resulted in the highest rate of survival (87%). According to the results of pharmacokinetic
studies on phages, compared to other administration routes, phages reached the target at
higher concentrations and faster when given via the i.p. route.
2.10. Oral Phage Therapy
Oral formulations of bacteriophages are generally used to target acute gastrointestinal
infections. However, there are a number of factors for the treatment to be successful,
including stability and effective phage dose at the site of infection. A significant decrease in
phage titers occurs before the phages reach the site of infection. Phage viability and activity
decrease as a result of gastric acidity and digestive enzymes such as pepsin and pancreatin.
Thus, it is necessary to prepare new dosage forms. Vinner et al. [67] encapsulated enteric
bacteriophage K1F against E. coli in a pH-responsive solid formulation and examined the
viability of these bacteriophages at different pH values. They found that the microencapsulation process preserved phages for an extended period in the gastric acid environment.
The encapsulated phages were active in killing E. coli co-incubated with human epithelial
cells, which are normally stressed in the presence of the bacteria alone. There were no
stability problems for the encapsulated phages that were refrigerated for 4 weeks. Stanford
et al. [68] used polymer-encapsulated wV8, rV5, wV7 and wV11 phages, which are targeted
to E. coli. Then, the phages were exposed to pH 3.2 for 20 min. The unencapsulated phages
lost their activity while the encapsulated phages recovered 13.6% of their activity. Vinner
et al. [69] prepared the encapsulated bacteriophage Felix O1, which is specific to Salmonella,
by spray-drying, employing a commercially available pH-sensitive copolymer of methyl
methacrylate and methacrylic acid. The inclusion of trehalose in the formulation protected
the phages from the effects of spray-drying, maintaining the original phage titer. In a
different approach, Colom et al. [70] encapsulated the phages UAB_Phi20, UAB_Phi78
and UAB_Ph87 individually in a complex mixture of lipids that produced a net positive
charge on the ensuing liposomes. The encapsulation efficiencies were relatively high, in
the range of 47–49%, which is most likely the result of phage binding to the net cationic
lipid mixture. The encapsulated phages were more effective than plain phages in S. enterica
ser. Typhimurium-infected chickens at only 8 days following treatment, with a 3.9 log10
reduction [70].
3. Mycobacteriophage Therapy of Mycobacterium tuberculosis
There are more than 170 Mycobacterium species that have great variety in terms of
their pathogenicity in humans [71]. In addition to M. tuberculosis, M. ulcerans and M. leprae
cause Buruli ulcer and leprosy, respectively [72]. M. tuberculosis is a well-known example
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of an intracellular bacterium that localizes inside phagosomes of macrophages of the host
and causes tuberculosis (TB), which primarily affects the lungs [73]. Multi-drug-resistant
(MDR) TB cases have emerged in the late 1980s and early 1990s. These strains are resistant
to the first-line drugs against TB, rifampicin and isoniazid. In 2018, the World Health
Organization (WHO) reported that 484,000 new TB patients failed to respond to rifampicin.
Seventy-eight percent of these patients were infected with MDR-TB [74].
Alternative treatment approaches for MDR-TB have become crucial to managing
the disease. One of these approaches is mycobacteriophage therapy. More than 70 years
have passed since mycobacteriophages were isolated for the first time [75]. So far, 11,282
mycobacteriophages have been isolated [76].
Bacteriophages can enter macrophages by four main routes [77] (Figure 3): (1) Endocytotic uptake of the bacteriophage alone; (2) entry into the macrophage via pathogenic bacteria together with the bound phage; (3) uptake of the bacteriophage and non-pathogenic
bacteria; (4) internalization of the bacteriophage that has been encapsulated by poly-mers
or liposomes. Relatively non-pathogenic vectors, such as M. smegmatis, can be used to
deliver phages to the same intracellular compartments where M. tuberculosis is found [78].
The lytic mycobacteriophage TM4 was delivered in this manner to M. tuberculosis-infected
RAW264.7 macrophages and reduced the bacterial counts. By contrast, the phage alone was
ineffective. The administration of the M. smegmatis-TM4 complex to M. avium-infected mice
significantly decreased the bacterial counts in the spleen, whereas TM4 or M. smegmatis
alone had no effect [79]. The authors suggested that phage resistance (which was observed
in their study) could be overcome by the use of phage cocktails.

Figure 3. Possible cellular entry pathways of bacteriophages. The pathways 1–4 are described
in the text. Dark red hexagons, bacteriophage; brown-filled ovals, bacteria (pathogenic bacteria,
P; non-pathogenic bacteria, N); curly lines within bacteria, bacteriophage nucleic acids; orange
ovals, endosomal vesicles; blue-gray circles and M, microcapsules; dotted lines, degrading bacterial
membrane (reproduced with permission from Nieth et al., 2015 [77]).

The mycobacteriophage D29 was used to treat M. tuberculosis H37Rv inside RAW
264.7 macrophages [80]. The phage, administered twice over a 24-h period, caused an
eight-fold reduction in the CFUs, indicating that it was able to access the intracellular
compartment occupied by the bacteria. The phage was encapsulated in (or associated with)
liposomes comprising phosphatidylcholine, cholesterol and Tween-80 and which were
sized by extrusion through membranes of 400-nm diameter. This formulation applied to
infected macrophages resulted in a two-fold improvement of the antimycobacterial effect
over that of the free phage. In an in vitro model of tuberculous granuloma developed
from peripheral blood mononuclear cells of patients with TB, liposomal phage was about
nine-fold more effective than free D29 [81].
Aerosolized bacteriophage D29 was used to investigate the possibility of protecting
mice against M. tuberculosis infection [62]. This treatment significantly decreased the M.
tuberculosis counts in the lungs 1 day and 3 weeks after challenge. The authors suggested
that aerosolized mycobacteriophages may be useful in conferring additional protection to
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healthcare workers who may be at risk of exposure to tuberculosis. D29 was also employed
in a murine footpad model in treating Buruli ulcer, which is caused by Mycobacterium
ulcerans [82]. In infected patients, the bacterium causes necrosis of the skin, subcutaneous
tissue as well as bone. If the disease reaches advanced stages, surgical resection of the skin
may be necessary. The subcutaneous injection of D29 resulted in a decrease in pathology
and mycobacterial counts. It also caused increased production of cytokines, including
IFN-γ, in the footpads and draining lymph nodes. Endolysins are bacteriophage-encoded
peptidoglycan-disrupting enzymes synthesized at the last stage of the phage life cycle in
the infected bacteria [83]. One endolysin, lysine B, was found to lyse M. ulcerans infecting
the footpad of experimental mice [84].
Developing mycobacteriophages into efficient therapeutic pharmaceuticals has focused on improving their uptake into macrophages and co-localization with the intracellular mycobacteria. In this process, however, it is essential to maintain the stability of the
formulation and the vitality of the mycobacteriophages. In the next step, well-established
in vitro and in vivo studies of effective and stable mycobacteriophage formulations are
expected to translate into clinical studies with successful outcomes.
4. Bacteriophage Therapy of Pseudomonas aeruginosa
P. aeruginosa are Gram-negative aerobic bacteria classified as Gammaproteobacteria
that can cause severe necrotizing bronchopneumonia, burn wound infections, urinary tract
infections, otitis externa, eye infections and bacteremia [85].
In a murine model of sepsis caused by P. aeruginosa via the gut, the lytic phage
KPP10 administered orally increased the survival rate from 0% in the controls to 67% [86].
The number of viable bacteria in the liver, spleen and blood were reduced in the phagetreated group, as were the levels of inflammatory cytokines in the liver and blood. Imipenemresistant P. aeruginosa delivered i.p. resulted in bacteremia and killed 100% of experimental
mice within 24 h [87]; the i.p. administration of the phage ØA392 within 1 h of infection
was able to rescue all the animals. The phages were found in blood within 2 h. However,
delivery of the phage at 3 h post-infection resulted in only 50% survival. In a murine
burn-wound model, fatal infection by P. aeruginosa could be reduced to 87% survival when
a three-phage cocktail was given i.p. [67]. The phages rapidly distributed to the blood, liver
and spleen. In a similar study, i.p. delivery of multi-drug-resistant P. aeruginosa caused fatal
bacteremia in mice within 2 d [88]. A phage strain that had lytic activity against numerous
multi-drug-resistant P. aeruginosa given 45 min after bacterial infection resulted in 100%
survival. Fifty percent of the animals could be saved even when the therapy was applied
at a point where the animals were sick. The therapeutic effect of the phage was also shown
not to be the result of a non-specific immune response.
When mice with acute lung infection with intranasally administered bioluminescent P.
aeruginosa, which resulted in the death of all the animals within 2 days, were treated with
bacteriophage PAK-P1-to-bacterium ratios of 1:1 and 10:1 via the same route, they survived
until the end of the 12-day experiment [89]. Bacteriophage treatment also prevented lung
infection when administered 24 h before inoculation of bacteria. Two phages were isolated
from wastewater, the myovirus ϕNH-4 and the podovirus ϕMR299-2, and used to treat
P. aeruginosa infection in murine lungs [90]. The pathogen was reduced by three to four
orders of magnitude in 6 h. A mixture of the two phages could kill biofilms of mucoid and
nonmucoid strains of P. aeruginosa on CFBE41o-cystic fibrosis bronchial epithelial cells, and
the phages were shown to multiply over 24 h.
Phage GNCP treatment of multi-drug-resistant P. aeruginosa infection in diabetic and
non-diabetic mice, which caused fatal bacteremia within 2 d, at a 10:1 ratio of phage:bacteria
resulted in protection of 90% of diabetic animals and 100% of non-diabetic animals [91].
Bacteriophages were also effective in reducing inflammation in a murine acute infection
model of P. aeruginosa [92]. The titer of phage PEV31 delivered intratracheally to mice
without bacterial infection decreased with a t1/2 of about 8 h. In mice infected with
P. aeruginosa, the phage titer increased by about two orders of magnitude in 16 h, and
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bacterial growth was suppressed, whereas it increased exponentially in the untreated
animals [93].
5. Clinical Cases Treated with Bacteriophages
Lung transplant recipients with life-threatening multi-drug-resistant P. aeruginosa or
Burkholderia dolosa infections were treated with lytic bacteriophages targeting the bacterial
strains, together with antibiotics [94]. Two patients with P. aeruginosa infection responded
to the treatment and could leave the hospital. The patient with recurrent B. dolosa infection
did not respond to bacteriophage therapy. The safety and feasibility of phage treatment of
patients with various infections at a single center in the U.S. was established, although two
of the 10 patients described did not respond to therapy [95].
P. aeruginosa can infect prosthetic vascular grafts that often do not respond to antibiotic
therapy [96]. The bacteriophage OMKO1, together with ceftazidime, was used to treat
infection of an aortic graft, which was resolved and did not recur.
Bacteriophage therapy was applied to chronic non-healing wounds that were infected
with E. coli, S. aureus and P. aeruginosa and that did not respond to antibiotic therapy [97].
The application of a cocktail of bacteriophages over the wounds every other day resulted
in the resolution of the infection after 3–5 doses. The wounds healed completely in seven
out of 20 patients and formed healthy granulation tissue and margins in the other patients.
In a trial that included 48 patients with non-healing wounds, a single phage against a
particular bacterial infection or multiple phages targeting multiple bacteria were applied
every other day for 5 to 7 days [98]. The cure rate was 81%, with diabetic patients having a
lower rate (74%).
A 65-year-old woman with a post-operative left-eye corneal abscess and interstitial
keratitis was treated for many years with various antibiotics but remained positive for
vancomycin-intermediate sensitivity S. aureus in the nasal cavity, skin and eye [99]. She
then underwent topical and intravenous phage therapy with the bacteriophage SATA-8505.
This phage strain is active against the methicillin-resistant S. aureus strain USA300 and has
been patented. Ocular and nasal cultures from the patient 3 and 6 months after therapy
showed no infection.
6. Conclusions
The importance of phage therapy for bacterial infections has been recognized by both
academic institutions and the pharmaceutical industry. The Center for Phage Applications
and Therapeutics at the University of California San Diego, the Center for Phage Technology
at Texas A&M University at College Station and the Pittsburgh Bacteriophage Institute at
the University of Pittsburgh are examples of academic institutions. Companies focusing on
phage therapy include the Eliava Institute and affiliated companies in Tblisi, InnoPhage in
Porto, Adaptive Phage Therapeutics in Gaithersburg, Intralytics in Columbia, Maryland,
and Armata Pharmaceuticals in Marina Del Ray. Thus, it appears that phage therapy
will be widely available, next to newly developed antibiotics, to teat multi-drug-resistant
infections.
Although small-scale studies have demonstrated the potential of phage therapy for
bacterial infections, especially in cases of severe antibiotic resistance, the widespread
applicability of this therapy has not been shown in clinical trials [100]. In a clinical trial
involving patients with urinary tract infections, phages administered directly into the
bladder were no more effective than placebo or antibiotics [101]. Burn-wound infections
with P. aeruginosa were treated with either the phage PP1131 or 1% sulfadiazine silver
emulsion cream, the standard of care, in a multi-center clinical trial. Phage treatment at the
relatively low dose of 106 plaque-forming units per mL was not as effective as the standard
of care [102].
To supplement phage therapy, it may be possible to utilize antibiotics and phages
simultaneously in some circumstances. In an in vitro study of P. aeruginosa and S. aureus
biofilms, either alone or in combination, the phage EPA1 that infects P. aeruginosa and
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different antibiotics, the simultaneous application of the two agents drastically increased
the cytotoxicity against the bacteria [103]. The addition of gentamicin or ciprofloxacin after
a 6-h treatment with the phage appeared to eradicate the bacterial biofilms, with higher
gentamicin concentrations being necessary for treating combined biofilms.
Clinical trials of bacteriophage therapy of bacterial infections are still at an early stage.
Optimal conditions of phage use, including their concentration, the time and sequence
of administration and their combination with the appropriate antibiotics, are likely to
establish the effectiveness and reliability of this medicine. Even until such standards are
established, their ability to save the patient described in the Introduction is a most welcome
addition to the practice of medicine.
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